Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.

Topline final safety and efficacy results for the full 36 weeks of treatment from all participants will be available in ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

The U.S. has registered over half a million clinical trials since 2000. Here's a look at the business and ethics of human ...

A routine blood test identified abnormalities, leading to follow-up tests. A hematologist diagnosed Evans with early-stage ...

MOG antibody-associated disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients ...

AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study OverviewAstraZeneca is running a Phase IIb study titled “A Phase ...

TD Cowen initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating. Rapt Therapeutics’ ozureprubart, an improved IgE monoclonal antibody versus Xolair for food allergy and Chronic Spontaneous ...

MOG Antibody-associated Disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Rare blood cancers, once less studied, are now gaining fresh scientific momentum that is driving breakthroughs in disease understanding and treatment ...